Nonhypoglycemic Effects of Thiazolidinediones
Authors: Jose Manuel Quesada-Gómez, Ignacio Serrano-Alferez
Journal: Annals of Internal Medicine (2001)

Letters4 December 2001Nonhypoglycemic Effects of ThiazolidinedionesJose Manuel Quesada-Gómez, MD and Ignacio Serrano-Alferez, MDJose Manuel Quesada-Gómez, MDHospital Universitario Reina Sofía; 14004 Córdoba, SpainSearch for more papers by this author and Ignacio Serrano-Alferez, MDHospital Universitario Reina Sofía; 14004 Córdoba, SpainSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-11-200112040-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Thiazolidinediones are a new class of oral antidiabetic agents. Two agents in this class, rosiglitazone and pioglitazone, were recently approved by the U.S. Food and Drug Administration. The glucose-lowering effect of thiazolidinediones is mediated at two levels: 1) a decrease in insulin resistance at the muscular levels, thereby increasing glucose uptake, and 2) an inhibition of hepatic glucose production. These biological activities are probably mediated by decreased production of resistin, a polypeptide specifically expressed and secreted by adipocytes (1). Thiazolidinediones bind and activate a novel receptor called peroxisome proliferator-activated receptor g (PPARg), an orphan member of the ...References1. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al . The hormone resistin links obesity to diabetes. Nature. 2001;409:307-12. [PMID: 11201732] CrossrefMedlineGoogle Scholar2. Vamecq J, Latruffe N. Peroxisome proliferator-activated receptors (PPARS) and their implications in diseases. Current Opinion in Endocrinology and Diabetes. 2000;7:8-18. CrossrefGoogle Scholar3. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;134:61-71. [PMID: 11187421] LinkGoogle Scholar4. Nuttall ME, Gimble JM. Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone. 2000;27:177-84. [PMID: 10913909] CrossrefMedlineGoogle Scholar5. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115-37. [PMID: 10782361] MedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Hospital Universitario Reina Sofía; 14004 Córdoba, Spain PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoNonhypoglycemic Effects of Thiazolidinediones Akhil A. Parulkar , Merri L. Pendergrass , Ramona Granda-Ayala , Tri Richard Lee , and Vivian A. Fonseca Metrics Cited ByEffect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia 4 December 2001Volume 135, Issue 11Page: 1007-1008KeywordsAdipocytesBoneBone developmentBone resorptionGlucoseSteroidsTranscription factorsType 2 diabetesVitamin DVitamin D deficiency ePublished: 4 December 2001 Issue Published: 4 December 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...